Rubius Therapeutics Inc. Stock News

Company Earns Spot on Both Lists for Second Year in a Row Company Earns Spot on Both Lists for Second Year in a Row

Metropolitan Life Insurance Co NY boosted its position in Rubius Therapeutics, Inc. (NASDAQ:RUBY) by 128,180.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,828 shares of the company’s stock after purchasing an additional 12,818 shares during the quarter. Metropolitan Life Insurance […]

CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Evercore ISI 4 th Annual HealthCONx Conference on November 30, 2021, at 10:55 a.m. EST.

California State Teachers Retirement System raised its position in Rubius Therapeutics, Inc. (NASDAQ:RUBY) by 15.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,150 shares of the companys stock after purchasing an additional 8,157 shares during the quarter. California []

MetLife Investment Management LLC boosted its position in Rubius Therapeutics, Inc. (NASDAQ:RUBY) by 17.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,756 shares of the companys stock after acquiring an additional 2,464 shares during the quarter. MetLife Investment Management LLCs holdings in []

Titan Pharmaceuticals (NASDAQ:TTNP) and Rubius Therapeutics (NASDAQ:RUBY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Insider and Institutional Ownership 5.9% of Titan Pharmaceuticals shares are owned by institutional investors. Comparatively, []

Rubius Therapeutics (RUBY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an e

CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an e

CAMBRIDGE Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ent

Rubius Therapeutics (RUBY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.

Preclinical Data Show RTX-240 Promotes T Cell and NK Cell Activity Demonstrating Efficacy and Improved Safety Compared with a 4-1BB Agonist Antibody Preclinical Data Show RTX-240 Promotes T Cell and N

CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ent

Rubius just released some early data at the AACR.